Literature DB >> 11520988

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.

J Götz1, F Chen, J van Dorpe, R M Nitsch.   

Abstract

beta-Amyloid plaques and neurofibrillary tangles (NFTs) are the defining neuropathological hallmarks of Alzheimer's disease, but their pathophysiological relation is unclear. Injection of beta-amyloid Abeta42 fibrils into the brains of P301L mutant tau transgenic mice caused fivefold increases in the numbers of NFTs in cell bodies within the amygdala from where neurons project to the injection sites. Gallyas silver impregnation identified NFTs that contained tau phosphorylated at serine 212/threonine 214 and serine 422. NFTs were composed of twisted filaments and occurred in 6-month-old mice as early as 18 days after Abeta42 injections. Our data support the hypothesis that Abeta42 fibrils can accelerate NFT formation in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520988     DOI: 10.1126/science.1062097

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  474 in total

1.  Learning how scientists work: experiential research projects to promote cell biology learning and scientific process skills.

Authors:  Shubhik K DebBurman
Journal:  Cell Biol Educ       Date:  2002

Review 2.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats.

Authors:  Gao-Shang Chai; Dong-Xiao Duan; Rong-Hong Ma; Jian-Ying Shen; Hong-Lian Li; Zhi-Wei Ma; Yu Luo; Lu Wang; Xin-Hua Qi; Qun Wang; Jian-Zhi Wang; Zelan Wei; Darrell D Mousseau; Li Wang; Gongping Liu
Journal:  Neurosci Bull       Date:  2014-11-12       Impact factor: 5.203

4.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

Review 5.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 6.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

7.  Amyloid peptide toxicity and microtubule-stabilizing drugs.

Authors:  Mary L Michaelis; Yingxue Chen; Sarah Hill; Emily Reiff; Gunda Georg; Antonie Rice; Kenneth Audus
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 8.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 9.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

Review 10.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.